Date of Birth January 29th 1971 in Lyon, France
2011, Hability to direct research project, Université Montpellier 2, Montpellier, France
2000, Ph.D., Neurosciences, Université de la Méditerranée, Marseille, France
2011- Chargé de Recherche 1 INSERM and Group leader, Institute for Neurosciences of Montpellier, Montpellier, France.
2008-10 Group leader and Oberassistant-Dozenter, ETH Zurich, Zurich, Switzerland.
2005-08 Senior research assistant, ETH Zurich, Zurich, Switzerland.
2000-05 Research fellow, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
1997-2000 Graduate student, INSERM U364, Marseille, France.
1996-99 University teaching assistant, Université de la Méditerranée, Marseille, France.
1995-97 Visiting graduate student, MRC Neuropharmacology Unit, Oxford University, UK.
Awards and Funding
ERC starting grant consolidator (1 918 000 euros), April 2013-March 2018
ARSEP (65 000 euros), Principal Investigator, March 2012- April 2013.
Avenir INSERM (360 000 euros), Principal Investigator, January 2011- December 2013.
Swiss National Fund (SNF) project funding grant (243 000 CHF), Principal investigator, May 2008-May 2011
ETH Zurich grant (208 000 CHF), Co-Principal investigator, May 2006-May 2009
Invited presentation and meeting
Chair at the Translational Meeting on Peripheral Neuropathies (2013)
Invited presentation to the Translational Meeting on Peripheral Neuropathies (2013), Krabbe Translational Research Network (2013), Gordon conference on myelin (2012), the 42nd meeting of the American Society for Neurochemistry (2011), the myelin satellite meeting of the ISN meeting (2011), and to the 1st meeting of the German Myelin Network (2011)
Co-organizer of the 2nd and 3rd symposium of the Institute of Cell Biology, ETH Zurich (2006-2008)
Fast nerve conduction requires peripheral axons to be myelinated by Schwann cells. This myelination process is the result of an intense collaboration between both cell types. The importance of this collaboration is underlined by the extend and the severity of peripheral neuropathies.
Our first goal is to understand the molecular basis of the myelination process both in Schwann cells and axons and to investigate how these molecular pathways could be involved in peripheral neuropathies etiology.
Our second goal is to use our expertise in the use of viral vectors to transduce peripheral nerve cells in vivo to design a gene therapy for peripheral nerve diseases.